Amid Daiichi-Ranbaxy row, Delhi HC restricts sale of 'SRL' trademark

The HC has been hearing Daiichi's petition seeking the implementation of Rs 3,500 cr Singapore tribunal arbitral award passed in its favour, against former promoters of Fortis Healthcare

The Delhi High Court has put a restrain on selling of or creating any third party interest in the 'SRL' trademark after Japanese pharma major Daiichi Sankyo sought to attach and sell it to recover the amount due from former Ranbaxy promoters Malvinder Mohan Singh and Shivinder Mohan Singh.

Justice Rekha Palli also sought response of the Singh brothers on Daiichi's plea seeking sale of the SRL and allied trademarks and to restrain Judgment Debtors (Headway Brands Private Limited) from alienating, transferring, selling or in any manner creating any third-party interest in the equity shares or ownership of the firm or any